

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hansoh Pharmaceutical Group Company Limited
翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT

**RISVUTATUG REZETECAN FOR INJECTION (HS-20093) FOR SMALL
CELL LUNG CANCER INCLUDED IN PRIORITY REVIEW AND
APPROVAL PROCEDURE OF THE NMPA**

The board of directors (the “**Board**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**”) and together with its subsidiaries, the “**Group**”) is pleased to announce that, on August 21, 2026, based on the positive results from the pivotal Phase III ARTEMIS-008 trial on risvutatug rezetecan for injection (HS-20093) (the “**Product**”), the indication for small cell lung cancer (SCLC) after the failure of prior platinum-based chemotherapy of the Product has been included in the Priority Review and Approval Procedure of the National Medical Products Administration (the “**NMPA**”).

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, September 11, 2026

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Ms. Sun Yuan and Dr. Lyu Aifeng as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai, Ms. Yang Dongtao and Mr. Yan Jia as independent non-executive directors.